Uppsala University is a comprehensive research-intensive university with a strong international standing. Our ultimate goal is to conduct education and research of the highest quality and relevance to make a long-term difference in society. Our most important assets are all the individuals whose curiosity and dedication make Uppsala University one of Sweden’s most exciting workplaces. Uppsala University has over 54,000 students, more than 7,500 employees and a turnover of around SEK 8 billion.
The research group of Molecular Geriatrics is located at the Rudbeck Laboratory and is closely linked to the memory clinic at the Uppsala University Hospital. Our research is focused on protein aggregation in neurodegenerative diseases. The research is conducted in collaboration with other research groups internationally and in Sweden, as well as with various pharmaceutical companies.
Alzheimer’s disease is the second most common neurodegenerative disease and is characterized by pathologically altered forms of the protein amyloid-beta in different parts of the brain. The treatment, which is aimed at increasing the levels of the signal substance acetyl choline, only relieves symptoms and is not aimed at the underlying disease process. There is therefore a great need to develop new therapies. One possibility may be to influence the formation of amyloid-beta with new gene therapeutic methods. The gene encoding this protein, APP, may in rare cases be mutated, leading to the formation of either more amyloid-beta, or an altered form of the protein. However, the vast majority of cases are sporadic, but even for these there is evidence that increased expression of APP is central in the disease process. In an ongoing project, the research team is developing a gene editing method to reduce the formation of amyloid-beta.
The researcher will carry out studies in which mutated or non-mutated forms of APP are expressed in cell and animal models of the disease. With CRISPR/Cas9, delivered by transfection or virus-mediated transduction, the gene is inactivated. Sanger- and Next Generation sequencing are used to detect effects at the DNA level. With quantitative PCR RNA levels are examined and with Western blot and immunochemical methods the presence of proteins in cell preparations and tissues are studied. Various methods for evaluating cell functions are also used. The overall goal of the study is to contribute to the development of new treatment methods for Alzheimer’s disease. The work is carried out at Uppsala University (Rudbeck Laboratory).
We welcome applications with a PhD in the biomedical field and experience in molecular biology, including work on experimental mouse models. Previous experiences in gene editing techniques, production and utilization of AAV-vectors as well as cell culture, transfection, and animal handling are required. The applicant also needs to have a good knowledge of written and spoken English.
The application should contain a cover letter (maximum 1 page) describing the applicant’s research interests, an updated CV with a list of publications, copies of diplomas and certificates of higher academic degrees as well as contact details (name, e-mail, phone number) of two referees.
About the employment
The employment is a temporary position of 2 years according to central collective agreement. Scope of employment 100 %. Starting date 2022-11-01 or as agreed. Placement: Uppsala.
For further information about the position, please contact: Professor Martin Ingelsson (email@example.com)
Please submit your application by 15th August 2022, UFV-PA 2022/2409.
Are you considering moving to Sweden to work at Uppsala University? Find out more about what it´s like to work and live in Sweden.
Please do not send offers of recruitment or advertising services.
Submit your application through Uppsala University’s recruitment system.
Deadline: 2022-08-15 at 23:59
Unit: Department of Public Health and Caring Sciences
Post expires on Monday August 15th, 2022